solute carrier family 15 member 4Genealiases: FP12591 · PHT1 · PTR4
Q-omics provides the consensus-scored SLC15A4 profile across patient tissues and cancer cell-line models. SLC15A4 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SLC15A4 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, SLC15A4 RNA expression shows 19,071 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, KIRC, and THYM as cancer lineages where SLC15A4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC15A4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC15A4 survival associations across molecular data types. SLC15A4 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (9) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC15A4 RNA expression–survival associations across cancer types. High SLC15A4 expression shows unfavorable associations in MESO, LIHC, HNSC and LGG, but favorable associations in KIRC and SCLC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for SLC15A4 RNA expression.
This table summarizes SLC15A4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for SLC15A4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC15A4 shows higher tumor expression in KIRC, HNSC, KIRP, THCA, COAD and BLCA. The KIRC box plot shows higher SLC15A4 RNA expression in tumor versus normal tissue (log2 FC = +1.977, t-test p < 0.001).
This table shows molecular features associated with SLC15A4 in patient tissues and cancer cell lines. In patient samples, SLC15A4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC15A4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Lymphoma.
